Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort
Top Cited Papers
- 13 April 2018
- journal article
- research article
- Published by Elsevier BV in European Journal Of Cancer
- Vol. 96, 17-24
- https://doi.org/10.1016/j.ejca.2018.03.015
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Metastatic breast cancer: prolongation of survival in routine care is restricted to hormone-receptor- and Her2-positive tumors.SpringerPlus, 2014
- Prognostic factors in patients with metastatic breast cancer at the time of diagnosisPathology - Research and Practice, 2014
- Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: Final Results From the EGF104900 StudyJournal of Clinical Oncology, 2012
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast CancerNew England Journal of Medicine, 2012
- Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised studyThe Lancet, 2011
- Lapatinib plus Letrozole as First-Line Therapy for HER-2+ Hormone Receptor–Positive Metastatic Breast CancerThe Oncologist, 2010
- A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analysesBreast Cancer Research and Treatment, 2008
- From best evidence to best practice: effective implementation of change in patients' careThe Lancet, 2003
- Impact of Follow-up Testing on Survival and Health-Related Quality of Life in Breast Cancer PatientsJAMA, 1994
- Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow-upJAMA, 1994